Oxcia has been awarded a grant of 3 million SEK for a study in refractory AML patients
In tough competition in Swelife’s and Medtech4Health’s joint call for Collaborative projects for better health in 2022, Oxcia AB has been awarded a grant of 3 million SEK. The call aims to finance the development of innovative and sustainable life science solutions that contribute to strengthening Swedish competitiveness and increase patient benefit. The financed projects must have great potential to make care more efficient and contribute to sustainable growth. Oxcia is currently investigating OXC-101 in a phase 1 study in AML, MAATEO. It is an oral drug. Preliminary data is promising